Skip to main content
Equibles
BDTX logo

BDTX · Black Diamond Therapeutics, Inc.

Track BDTX — free

Use BDTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BDTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.84 +0.04 (+1.94%)
Russell 2000 member Rebalance outlook locked
Market Cap
$107.44M
Shares
57.45M
Volume · Oct 7 492.97K Avg daily vol (3M) 666.92K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.80 Open$1.94 Day$1.80–1.96 52W close$1.61–4.87 Avg vol 30d577K Short int5.1M · 9.0% float · 10.1d Short vol64% Last earningsDec 3, 2025 DataJan 2020–Oct 2026 Filing10-Q · Aug 5

Up next

Latest filing: 10-Q
filed Aug 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$42.55M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$19.19M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.0%
Year over year · more shares
Price change (1Y)
-54.1%
Trailing year
Short interest
9.0%
Latest settlement · 10.1 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 15 · calm Equity put/call 0.57
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −20%
below
Price vs 50-day avg −9%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 6%
near low
Momentum
relative strength
Very Weak
1-month return −14%
trailing
6-month return −37%
trailing
YTD return −26%
this year
Relative strength −49%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Distributing
-6% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
8.96% of float · ▼ -15.9% MoM · 10.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
98 holders — mid 3-yr range
Squeeze score 68
elevated · 0–100
Fundamentals
Excellent
EPS growth +131%
Y/Y
Free cash flow $29.6M
Quant / Vol
risk profile
Very High
Volatility 81%
annualized · 1-yr
Max drawdown −67%
past year
ATR 5.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−20% Bearish
Price vs 50-day avg
−9% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
6% Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Distributing
-6% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
8.96% of float · ▼ -15.9% MoM · 10.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
98 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $2 · 6% Range high $5
vs 200-day avg -20% vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BDTX
Black Diamond Therapeutics, Inc.
this stock
$107.44M -25.9% — — 9.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +10.8% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.3% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +535.7% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
98
% held
61.8%
Net QoQ
-3.2M sh
Top holder
NEA Management Company, L…
Held Float
View
Held by Funds
Fund positions
97
View
Short & Settlement
Short Interest Falling
Shares short
5.1M
Days to cover
10.1d
Change
-971.1K sh
View
Short Volume
Short vol %
64%
As of
Oct 6, 2026
Short Total
View
Fails to Deliver
FTD shares
213
Value
$447
As of
Sep 10, 2026
View
Off-Exchange
Off-exchange %
35.7%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$22.4M
EPS diluted
$0.39
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 5, 2026
This year
9
View
Proposed Sales
Value
$310.0K
Shares
50.0K
Filed
Jul 31, 2024
View
Earnings & Events
Webcasts
Last webcast
Dec 3, 2025
View

Performance

5D 20D 120D MTD YTD
BDTX -3.7% -14.3% -37.3% -4.5% -25.9%
SPY +2.0% +1.7% +11.3% +2.2% +14.3%
vs SPY -5.7% -16.0% -48.6% -6.7% -40.2%
Key facts CIK 1701541 CUSIP 09203E105 13F (30d) 1 filings 1 filers Visit website Investor relations